LinkedIn company data shows Johannes Hille, former CEO, left in Apr 2026. No public layoffs, shutdown, or acquisition announcement surfaced in the sources reviewed.
SourceEarly, pain-free cancer detection.
Public company, workplace, funding, and market signals
X-ZELL is an award-winning Singapore-based medical technology company building next-generation cytology/precision oncology tools. Its platform combines direct-to-slide cryofixation, multiplex cryoimmunostaining, hybrid microscopy, and digital imaging to help labs extract richer diagnostic information from minimally invasive cytology samples, with a same-day workflow focus.
Primary product
Cryosuite / Cryophore multiplex cytology platform
Founded
2014
Headquarters
101 Cecil Street, #10-01 Tong Eng Building, Singapore 069533
Team size
1-10
Industry
Biotechnology
Sub-industry
Medical diagnostics / cytopathology (IVD)
Offices
0 jobs at X-Zell
Check back later for new openings
Business model
Stage
Seed+
Total raised
$5.7M
Latest round
Seed+ · Oct 2020
Latest amount
$4M
Leadership
Founder & CEO
Chief Commercial Officer; Managing Director
Global Head of Engineering and Product Development
Head of Laboratory / Head Of Laboratory Technical Manager
Head of Production
Head of Purchasing
Investors
Public signals point to a mission-driven, research-heavy, clinically collaborative culture. The company emphasizes global teamwork across Singapore, Thailand, Germany, and the US, frequent conference/demo activity, and close work with pathology and hospital partners. Public postings also suggest hands-on lab roles and a preference for execution in regulated medtech environments.
Compensation
No public salary bands were found. The company’s public LinkedIn/company signals show generally positive employee sentiment, including a 4.4/5 overall employer rating and a 4.0/5 compensation sub-rating, but that is not a substitute for disclosed pay data.
Pricing
Not publicly disclosed; appears to be B2B, with product, RUO, and OEM/private-label commercial models.
Differentiators
Technology
Customers
Competitors
Estimated revenue
~$10M ARR (estimate)
LinkedIn company data shows Johannes Hille, former CEO, left in Apr 2026. No public layoffs, shutdown, or acquisition announcement surfaced in the sources reviewed.
SourceX-ZELL · Apr 2026
X-ZELL said its Cryophore multiplex antibody panels achieved IVDR CE marking, positioning the panels for regulated laboratory workflows in Europe.
X-ZELL · Mar 2026
A peer-reviewed Acta Cytologica paper reported preliminary results for multiplex Cryoimmunostaining on FNAB and effusion samples.
X-ZELL · Mar 2026
X-ZELL commercially launched its first Cryophore panel line, initially for research use and with additional IVDR validation work ongoing.
X-ZELL · May 2025
X-ZELL previewed a standardized multiplex panel range built with experts and WHO guideline authors, positioned as a routine-cytology product line.
AP News / EIN Presswire · Jul 2024
AP carried a release describing interim German study results suggesting X-ZELL could reduce inconclusive diagnoses from minimally invasive sample material.